$Cingulate (CING.US)$
Cingulate Releases European Patent CTx-1301 for Lead Assets to Treat ADHD
Cingulate Inc.
Thursday, August 15, 2024, 7:45 PM GMT+85 min read
In this post:
Cingulate Inc.
KANSAS CITY, KS, August 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc., a biopharmaceutical company using its proprietary Precise Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation medicines, today announced a European patent for its primary asset, ctX-1301 (dimethyl phenidate) for the treatment of attention deficit hyperactivity disorder (ADHD).
The patent application was granted on August 14, 2024, and is EP patent number 3261625, which will include up to 30 European territories, including the United Kingdom. In addition to European patents, Cingulate also holds patents in Australia, Canada, and Israel, and pending patents in Hong Kong, the Republic of Korea, and the US.
“The grant of this patent is another significant milestone as Cingulate seeks to expand its reach beyond the US and address growing ADHD in Europe and other overseas regions...

$Cingulate (CING.US)$ Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
Cingulate Inc.
Thu, Aug 15, 2024, 7:45 PM GMT+85 min read
In This Article:
Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it ...

$Cingulate (CING.US)$ Everyone should know that the pullback is only temporary; this path will take a long time to run

$Cingulate (CING.US)$ Thank you all for persevering, we will continue before the market on Monday

$Clearmind Medicine (CMND.US)$ Psychedelics don't seem to be recognized?

$Cingulate (CING.US)$ Note: The patent covers up to 30 European regions, including the UK, and marks a key step in Cingulate's efforts to solidify its influence in the global ADHD market. Cingulate is also preparing to submit a New Drug Application (NDA) to the US Food and Drug Administration.
The drug is designed using Cingulate's Precise Timed Release Technology, which allows for precise timed release of the drug three times throughout the day. This innovation aims to provide patients with a full day of treatment with just one pill, and addresses ADHD treatment

$Cingulate (CING.US)$ Keep up the good work!

$Cingulate (CING.US)$ I think if they keep up after the market, the bears won't be able to sleep tonight 😅😆 Another wave, 20, the bears will be over. 😄

$Cingulate (CING.US)$ Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
At Novo Nordisk's Wegovy, doctors work to ensure health insurance for heart patients
Thanks to the doctors and researchers for their efforts! Save the suffering patients!